Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 28, 2015; 7(15): 1953-1963
Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1953
Hepatitis C: Treatment of difficult to treat patients
Eric G Hilgenfeldt, Alex Schlachterman, Roberto J Firpi
Eric G Hilgenfeldt, Department of Internal Medicine, University of Florida College of Medicine, Gainesville, FL 32610, United States
Alex Schlachterman, Roberto J Firpi, Department of Gastroenterology, Hepatology and Nutrition, University of Florida College of Medicine, Gainesville, FL 32610, United States
Roberto J Firpi, Section of Hepatobiliary Diseases and Transplantation, University of Florida, Gainesville, FL 32610, United States
Author contributions: Hilgenfeldt EG authored this review with assistance from Schlachterman A; Firpi RJ edited this review and provided guidance as to the content.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Roberto J Firpi, MD, MS, AGAF, Director of Hepatology and Liver Transplant, Section of Hepatobiliary Diseases and Transplantation, University of Florida, 1600 SW Archer Rd, MSB Rm M440, Gainesville, FL 32610, United States. roberto.firpi@medicine.ufl.edu
Telephone: +1-352-2739466 Fax: +1-352-3927393
Received: August 23, 2014
Peer-review started: August 26, 2014
First decision: December 17, 2014
Revised: May 29, 2015
Accepted: July 16, 2015
Article in press: July 17, 2015
Published online: July 28, 2015
Core Tip

Core tip: The current randomized controlled trials available show favorable sustained virologic responses in patients who are naive to treatment, non-cirrhotic, and not human immunodeficiency virus (HIV)-co-infected. What about patients who do not fit into these categories? In this review, we aim to discuss the currently approved and soon to be approved direct acting antivirals while focusing on their roles in patients that are treatment experienced, cirrhotic, or co-infected with HIV.